Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis (Q24794551)

1

object named as

Gordon R Bernard

0 references

author name string

William L Macias

2

0 references

David E Joyce

3

0 references

Mark D Williams

4

0 references

Joan Bailey

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

5

0 references

language of work or name

English

0 references

publication date

April 2003

0 references

1 April 2003

6 references

22 June 2019

4 August 2019

18 November 2019

27 November 2019

21 December 2019

1 February 2021

6 references

22 June 2019

4 August 2019

18 November 2019

27 November 2019

21 December 2019

1 February 2021

7

0 references

issue

2

0 references

page(s)

155-63

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Efficacy and safety of recombinant human activated protein C for severe sepsis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

The protein C anticoagulant pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=270661

The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12720562